Iconovo (ICO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Iconovo (ICO) has a cash flow conversion efficiency ratio of -0.035x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-5.48 Million ≈ $-589.95K USD) by net assets (Skr157.77 Million ≈ $16.98 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Iconovo (ICO) net asset quality to measure how much of total assets are equity-financed.
Iconovo - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Iconovo's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Iconovo (ICO) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Iconovo Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Iconovo ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ILYA Co. Ltd
KQ:058450
|
-0.047x |
|
Solo Brands, Inc.
NYSE:SBDS
|
-0.347x |
|
Techcential International Ltd
TWO:6616
|
0.038x |
|
SRJ Technologies Group Plc
AU:SRJ
|
-0.052x |
|
SACCHERIA F.LLI FRANCES.
F:YV1
|
N/A |
|
Tarjar Xairo Socimi SA
MC:YTAR
|
-0.062x |
|
Energy Action Ltd
AU:EAX
|
-0.017x |
|
MISSION GROUP PLC LS -10
F:M7K
|
N/A |
Annual Cash Flow Conversion Efficiency for Iconovo (2016–2025)
The table below shows the annual cash flow conversion efficiency of Iconovo from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Iconovo.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr117.92 Million ≈ $12.69 Million |
Skr-31.87 Million ≈ $-3.43 Million |
-0.270x | -42.31% |
| 2024-12-31 | Skr129.21 Million ≈ $13.91 Million |
Skr-24.54 Million ≈ $-2.64 Million |
-0.190x | +44.15% |
| 2023-12-31 | Skr113.53 Million ≈ $12.22 Million |
Skr-38.60 Million ≈ $-4.15 Million |
-0.340x | +30.53% |
| 2022-12-31 | Skr89.29 Million ≈ $9.61 Million |
Skr-43.70 Million ≈ $-4.70 Million |
-0.489x | -509.02% |
| 2021-12-31 | Skr137.03 Million ≈ $14.75 Million |
Skr-11.01 Million ≈ $-1.19 Million |
-0.080x | +53.31% |
| 2020-12-31 | Skr92.73 Million ≈ $9.98 Million |
Skr-15.96 Million ≈ $-1.72 Million |
-0.172x | -54.97% |
| 2019-12-31 | Skr108.79 Million ≈ $11.71 Million |
Skr-12.08 Million ≈ $-1.30 Million |
-0.111x | -599.12% |
| 2018-12-31 | Skr63.99 Million ≈ $6.89 Million |
Skr-1.02 Million ≈ $-109.38K |
-0.016x | +86.88% |
| 2017-12-31 | Skr31.52 Million ≈ $3.39 Million |
Skr-3.82 Million ≈ $-410.77K |
-0.121x | -117.56% |
| 2016-12-31 | Skr8.73 Million ≈ $939.49K |
Skr6.02 Million ≈ $647.74K |
0.689x | -- |
About Iconovo
Iconovo AB (publ) develops inhaled medicinal products in Sweden. The company offers ICOres, a multi-dose dry powder inhaler; ICOcap, a capsule based dry powder inhaler; ICOone, a single-dose disposable dry powder inhaler; and ICOpre, a pre-metered dry powder inhaler; and ICOone nasal single-dose dry powder inhaler for nasal use. It serves generic companies. The company has a collaboration agreeme… Read more